Wave Life Sciences

Wave Life Sciences (WVE) Q4 2025 Earnings

Reported Feb 26, 2026 at 7:37 AM ET · SEC Source

Q4 25 EPS

$-0.30

MISS 13.51%

Est. $-0.26

Q4 25 Revenue

$17.2M

BEAT +9.98%

Est. $15.7M

vs S&P Since Q4 25

-67.4%

TRAILING MARKET

WVE -57.3% vs S&P +10.1%

Full Year 2025 Results

FY 25 EPS

$-1.21

FY 25 Revenue

$42.7M

Market Reaction

Did WVE Beat Earnings? Q4 2025 Results

Wave Life Sciences posted a sharply weaker Q4 2025, with revenue collapsing to $17.24 million from $83.75 million a year earlier as collaboration payments from GSK fell dramatically, swinging the company to a net loss of $53.18 million compared to ne… Read more Wave Life Sciences posted a sharply weaker Q4 2025, with revenue collapsing to $17.24 million from $83.75 million a year earlier as collaboration payments from GSK fell dramatically, swinging the company to a net loss of $53.18 million compared to net income of $29.25 million in the prior-year period. EPS came in at -$0.30 for the quarter, reflecting the steep drop in partnership revenue alongside rising R&D expenditures of $52.81 million as Wave pressed forward aggressively across its clinical pipeline. Yet the headline losses obscure a company in deliberate growth mode, with management pointing to a substantially fortified cash position of $602.07 million, nearly double the $302.08 million held a year prior, providing a runway it expects to extend into Q3 2028. The most compelling part of the story sits in the pipeline, where WVE-007, its GalNAc-siRNA obesity candidate, demonstrated fat loss comparable to GLP-1 therapies while preserving muscle mass, and WVE-006 is now pursuing an accelerated approval pathway for alpha-1 antitrypsin deficiency, with a late-breaking oral presentation slot secured at a major lung conference in May 2026.

Key Takeaways

  • Revenue decline driven by lower GSK collaboration milestone and research funding recognition versus prior year
  • Cash position nearly doubled year-over-year due to financing proceeds and GSK milestone payments
  • R&D expense increases reflect advancement of obesity (WVE-007), AATD (WVE-006), and PNPLA3 (WVE-008) programs
24/7 Wall St

WVE YoY Financials

Q4 2025 vs Q4 2024, source: SEC Filings

“We entered 2026 focused on executing in two priority areas: accelerating development of WVE-007, our INHBE GalNAc-siRNA for obesity, and rapidly advancing our RNA editing portfolio, which includes WVE-006 for AATD and WVE-008 for PNPLA3 liver disease. WVE-007 is enabled by our leading RNAi capabilities supported by a differentiated and proprietary SpiNA design, and has the potential to be a transformative treatment approach for obesity. Our interim INLIGHT clinical data from the lowest therapeutic single-dose cohort demonstrated fat loss on par with GLP-1, favorable safety and tolerability, as well as the potential for once or twice a year dosing.”

— Paul Bolno, Q4 2025 Earnings Press Release